Taiwan S.E.
18:00:00 2024-05-16 EDT
5-day change
1st Jan Change
46.8
TWD
+1.96%
-1.06%
-18.47%
Chunghwa Chemical Synthesis & Biotech Co., Ltd. cancelled the transaction announced on March 11, 2024
Chunghwa Chemical Synthesis & Biotech Co., Ltd. announced a private placement of not more than 15,512,000 common shares on March 11, 2024. The transaction has been approved by the shareholders of the company.
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
03-28
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. cancelled the transaction announced on March 11, 2024
03-10
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
11-13
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
23-08-11
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Announces Cash Dividend for the Year 2022, Payable on August 18, 2023
23-06-27
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Announces Cash Dividend for the Year 2022
23-05-30
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
23-05-14
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
23-03-31
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. announced a financing transaction
23-03-06
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
22-11-10
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
22-08-11
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Announces Dividend, Payable on August 18, 2022
22-06-28
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Announces Appointment of Kuan Arthur¡G as Independent Director
22-05-25
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Approves Cash Dividend for 2021
22-05-25
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
22-05-13
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021
22-03-31
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
21-11-11
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Reports Earnings Results for the Second Quarter Ended June 30, 2021
21-08-13
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Announces Cash Dividend, Payable on August 18, 2021
21-07-01
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021
21-05-14
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020
21-03-30
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Reports Earnings Results for the Third Quarter Ended September 30, 2020
20-11-12
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Announces the Change of Representative of the Company's Legal Person Director
20-11-05
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Announces the Change of the Chairman and General Manager
20-11-05
CI
Chunghwa Chemical Synthesis & Biotech Co., Ltd.(TSEC:1762) added to S&P Global BMI Index
20-09-21
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO., LTD. is a Taiwan-based company principally engaged in the manufacture and distribution of biotechnology products and chemical synthetic products. The Company's biotechnology products include pravastatin, rapamycin, tacrolimus, everolimus, mycophenolate mofetil, mycophenolic acid sodium and others. Its non-biotechnology products include methocarbamol, guaifenesin, trandolapril, fluconazole, olopatadine, dexbromopheniramine maleate and glipizide, among others. Its products are applied in the manufacture of drugs for treatment of cough, diabetes, cardiovascular diseases, high blood pressure and immune system diseases. The Company distributes its products within domestic market and to overseas markets, including the rest of Asia, the Americas and Europe.
More about the company
Last Close Price
46.8
TWD
Average target price
48
TWD
Spread / Average Target
+2.56%
Consensus
1st Jan change
Capi.
-18.47% 113M -2.32% 90.45B +3.68% 41.45B -10.90% 33.57B +58.05% 25.73B -19.56% 14.73B -9.06% 12.82B -11.34% 11.7B -43.53% 11.44B +3.75% 8.79B
Biopharmaceuticals
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO., LTD. 
